This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (95)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Peter M. Schlag, MD, PhD

Arch Surg. 1992;127(12):1446-1450.

Abstract
• Of 77 patients with potentially resectable squamous cell carcinoma of the esophagus who were asked to participate in a phase III trial of treatment with either immediate surgery (n=24) or surgery plus preoperative chemotherapy (n=22), only 46 agreed to randomization. A priori, 13 patients chose chemotherapy before surgery and 18 patients chose surgery only. The complete chemotherapy program consisted of three cycles with fluorouracil, 1 g/m² per day for 5 days, and cisplatin, 20 mg/m2 per day for 5 days. The response rate to chemotherapy was 50% (17 of 34 patients). Side effects of therapy were higher than expected based on results of previous phase II studies. Two drug-related deaths were observed. The resectability rate for patients in the surgery only group was 79% (33 of 42 patients) compared with 70% (19 of 27 patients) for patients receiving chemotherapy. The postoperative rates of septic complications (41% [11 of 27 patients] vs 26% [11 of 42 patients]) and respiratory disorders (48% [13 of 27 patients] vs 31% [13 of 42 patients]) were higher for patients with preoperative chemotherapy than for those treated with surgery only. Surgery-related mortality was increased in the chemotherapy group (19% [five of 27 patients]) compared with the surgery only group (10% [four of 42 patients]). Patients responding to preoperative chemotherapy had prolonged survival (median, 13 months) compared with nonresponders (median, 5 months), but the median survival for the chemotherapy group and the surgery only group was identical (10 months). We conclude that the preoperative chemotherapy regime used in this multiinstitutional trial neither influences resectability nor increases the overall survival of patients with localized esophageal cancer. However, preoperative chemotherapy is associated with considerable side effects and a high postoperative mortality rate.

(Arch Surg. 1992;127:1446-1450)

Author Affiliations
From the Section of Surgical Oncology, Department of Surgery, University of Heidelberg, Germany. See the acknowledgment for a list of the contributing hospitals and responsible physicians.

Footnotes
Accepted for publication August 17, 1991.

Presented at the 44th Annual Cancer Symposium of the Society of Surgical Oncology, Orlando, Fla, March 27, 1991.

Reprint requests to Section of Surgical Oncology, Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 6900 Heidelberg, Germany (Dr Schlag).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma
Lee et al.
Ann. Thorac. Surg. 2005;80:1170-1175.
ABSTRACT | FULL TEXT  

High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer
Moore Joshi et al.
Clin. Cancer Res. 2005;11:2215-2221.
ABSTRACT | FULL TEXT  

Proliferation Potential-Related Protein, an Ideal Esophageal Cancer Antigen for Immunotherapy, Identified Using Complementary DNA Microarray Analysis
Yoshitake et al.
Clin. Cancer Res. 2004;10:6437-6448.
ABSTRACT | FULL TEXT  

Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer: Experience at a Single Institution
Malaisrie et al.
Arch Surg 2004;139:532-539.
ABSTRACT | FULL TEXT  

Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches
Koshy et al.
The Oncologist 2004;9:147-159.
ABSTRACT | FULL TEXT  

Multimodality therapy for resectable cancer of the thoracic esophagus
Entwistle and Goldberg
Ann. Thorac. Surg. 2002;73:1009-1015.
ABSTRACT | FULL TEXT  

Locoregional Cellular Immunotherapy for Patients with Advanced Esophageal Cancer
Toh et al.
Clin. Cancer Res. 2000;6:4663-4673.
ABSTRACT | FULL TEXT  

Does Paclitaxel Improve the Chemoradiotherapy of Locoregionally Advanced Esophageal Cancer? A Nonrandomized Comparison With Fluorouracil-Based Therapy
Adelstein et al.
JCO 2000;18:2032-2039.
ABSTRACT | FULL TEXT  

Surgical Management of Esophageal Carcinoma
Reed
The Oncologist 1999;4:95-105.
ABSTRACT | FULL TEXT  

PREOPERATIVE CHEMOTHERAPY VERSUS SURGICAL THERAPY ALONE FOR SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS: A PROSPECTIVE RANDOMIZED TRIAL
Law et al.
J. Thorac. Cardiovasc. Surg. 1997;114:210-217.
ABSTRACT | FULL TEXT  

Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus
Bosset et al.
NEJM 1997;337:161-167.
ABSTRACT | FULL TEXT  

The Role of Neoadjuvant Therapy in Surgically Resectable Esophageal Cancer
Swisher et al.
Arch Surg 1996;131:819-825.
ABSTRACT